secwatch.observer — SEC 8-K summary
======================================

Issuer:     Hoth Therapeutics, Inc. (HOTH)
CIK:        0001711786
Form:       8-K
Filed at:   2024-12-02T23:59:59+00:00
Accession:  0001213900-24-104567
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Hoth Therapeutics releases December 2024 corporate presentation highlighting pipeline and milestones
--------------------------------------------------------------------------------

- HT-001 Phase 2a for EGFR inhibitor skin toxicity: all sites active, enrolling open-label and double-blind; interim PK data expected Q1 2025.
- HT-KIT: pre-IND meeting with FDA successful; IND-enabling tox studies ongoing; IND submission target Q4 2025.
- HT-ALZ: US patent awarded Q3 2024; preclinical studies completed at WashU; pre-IND meeting planned for 2025.
- BioLexa Phase 1b data readout completed in 2023; proof-of-concept results shown; non-corticosteroid treatment for atopic dermatitis.
- 7.7M shares outstanding as of Nov 29, 2024; cash on hand sufficient to fund current clinical and preclinical programs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711786/000121390024104567/0001213900-24-104567-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711786/000121390024104567/ea0223333-8k_hoth.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-104567

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer